Form D · Biotechnology
Kronos Bio, Inc.
San Mateo, CA · CIK 0001741830
Offering snapshot reported Jul 15, 2019 · SEC filing
- Reported sold
- $105M Offering amount: $105M
- Investors reported
- 50 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 1, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2019 | Initial | $105,000,005 | No comparison | 50 | SEC filing |
| Jun 5, 2018 | Initial | $18,012,713 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-344261
Source: Form D, filed Jul 15, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sean Algeo | Executive |
| Rebecka Belldegrun, M.D. | Director |
| Arie S. Belldegrun, M.D. | Director |
| Norbert Bischofberger, Ph.D. | Director, Executive |
| Philip Gutry | Executive |
| Joshua A. Kazam | Director |
| Jacob Loven | Director |
| John C. Martin, Ph.D. | Director |
| Otello Stampacchia, Ph.D. | Director |
| David M. Tanen | Director, Executive, Promoter |
| Christopher Wilfong | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1300 S. El Camino Real Suite 300
San Mateo, CA, 94402
San Mateo, CA, 94402